ValenzaBio
Bethesda
About ValenzaBio
ValenzaBio is developing safe and effective treatment options for patients with autoimmune and inflammatory diseases. ValenzaBio implements biomarker-driven approaches to guide research and clinical development. Our pipeline includes several monoclonal antibodies targeting surface antigens to reduce pathogenic subpopulations of autoreactive cells. Our most advanced program has generated Phase 1 proof-of-concept in patients and we’re progressing preclinical programs focused on differentiated mechanisms of action. Our mission is to provide safe and effective treatment options for patients with unmet needs.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $93.9M
- Funding stage: M&A
- Last round: Series A (Apr 2021)
- Website: valenzabiotech.com
- Phone: 212 945 8929
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/valenzabio-132184 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.